Antibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 14240-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#14240-1-AP, RRID:AB_2197187
- Product name
- SUCLG2 antibody
- Antibody type
- Polyclonal
- Description
- SUCLG2 antibody (Cat. #14240-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: IHC, IP, WB, ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Mitochondrial Control of Proteasomal Psmb5 Drives the Differentiation of Tissue-Resident Memory T Cells in Patients with Rheumatoid Arthritis.
Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics.
SUCLG2 Regulates Mitochondrial Dysfunction through Succinylation in Lung Adenocarcinoma.
Pharmacologically targetable vulnerability in prostate cancer carrying RB1-SUCLA2 deletion.
Wu T, Su D, Zhang L, Liu T, Wang Q, Yan C, Liu M, Ji H, Lei J, Zheng M, Wen Z
Arthritis & rheumatology (Hoboken, N.J.) 2024 Jul 22;
Arthritis & rheumatology (Hoboken, N.J.) 2024 Jul 22;
Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics.
Peng X, Zhao H, Ye L, Hou F, Yi Z, Ren Y, Lu L, Chen F, Lv J, Wang Y, Cai H, Zheng X, Yang Q, Chen T
Clinical cancer research : an official journal of the American Association for Cancer Research 2024 Jul 15;30(14):3059-3072
Clinical cancer research : an official journal of the American Association for Cancer Research 2024 Jul 15;30(14):3059-3072
SUCLG2 Regulates Mitochondrial Dysfunction through Succinylation in Lung Adenocarcinoma.
Hu Q, Xu J, Wang L, Yuan Y, Luo R, Gan M, Wang K, Zhao T, Wang Y, Han T, Wang JB
Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2023 Dec;10(35):e2303535
Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2023 Dec;10(35):e2303535
Pharmacologically targetable vulnerability in prostate cancer carrying RB1-SUCLA2 deletion.
Kohno S, Linn P, Nagatani N, Watanabe Y, Kumar S, Soga T, Takahashi C
Oncogene 2020 Aug;39(34):5690-5707
Oncogene 2020 Aug;39(34):5690-5707
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- human heart tissue were subjected to SDS PAGE followed by western blot with 14240-1-AP(SUCLG2 antibody) at dilution of 1:500
- Sample type
- tissue
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- Immunohistochemical of paraffin-embedded human colon cancer using 14240-1-AP(SUCLG2 antibody) at dilution of 1:100 (under 10x lens)
- Sample type
- tissue
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The SUCLG2 antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human SUCLG2. This antibody recognizes human, mouse, rat antigen. The SUCLG2 antibody has been validated for the following applications: ELISA, WB, IHC analysis.